Chugai signed a joint research and licencing agreement with Singapore-based biotechnology firm Gero to create new antibody drug candidates ...

The pulmonary arterial hypertension market is forecast to grow at a CAGR of 2.0% from 2024 to 2034, reaching $9.35bn across 7MM.

Several medical organisations have filed a lawsuit against RFK Jr and the HHS over recent changes to the US immunisation schedule.

GSK has concluded the acquisition of efimosfermin alfa, an investigational therapeutic for serious liver disease, from Boston Pharmaceuticals ...

The Swiss Agency for Therapeutic Products (Swissmedic) has approved Novartis’ Coartem (artemether-lumefantrine) Baby, described as the first malaria medicine for newborns and young infants. Known as ...

The DoH and Children’s National Hospital in the US have signed a MoU to advance paediatric cell and gene therapy.

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

The U.S. Food and Drug Administration’s (FDA’s) evolving guidance on Computer Software Assurance and AI/ML-Based Software ...

A discussion on formulation development, contract services, and some of the critical considerations when moving from molecule to clinic.

Biocon Biologics’ Denosumab biosimilars, Vevzuo and Evfraxy, have received marketing authorisation in the European Union (EU).

BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads.

Lynozyfic has the potential to be administered monthly, giving it an advantage over J&J and Pfizer’s marketed products.